Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3883095 | 1.00 | NR3C2 (0.47) | NR3C2NR3C1 | |
| SCHEMBL4697278 | 1.00 | NR3C2 (0.47) | NR3C2NR3C1 | |
| SCHEMBL1774481 | 1.00 | NR3C2 (0.47) | NR3C2NR3C1 | |
| SCHEMBL4469875 | 0.86 | NR3C1 (0.35) | NR3C2NR3C1 | |
| SCHEMBL6251969 | 0.86 | NR3C2 (0.42) | NR3C2NR3C1 | |
| SCHEMBL12549422 | 0.85 | NR3C2 (0.36) | NR3C2NR3C1 | |
| SCHEMBL1716860 | 0.82 | NR3C1 (0.40) | NR3C2NR3C1 | |
| SCHEMBL1716861 | 0.82 | NR3C1 (0.40) | NR3C2NR3C1 | |
| SCHEMBL4474597 | 0.81 | NR3C2 (0.44) | NR3C2NR3C1 | |
| SCHEMBL14470146 | 0.80 | IDO1 (0.33) | NR3C2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869003-B1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2013-05-15 | — | — | EP | disclosed |
| EP-2013185-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-8178573-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-05-15 | — | — | US | disclosed |
| US-8093281-B2 | Indazoles as glucocorticoid receptor ligands | GLAXO GROUP LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-7943651-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20100016331-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-7579469-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579469-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579469-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-2086942-A2 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2009-08-12 | — | — | EP | disclosed |
| US-6897224-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2005-05-24 | — | — | US | disclosed |
| EP-1492771-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-05 | — | — | EP | disclosed |
| EP-1133486-B1 | NONSTEROIDAL ANTIINFLAMMATORIES | SCHERING AG (DE) | 2004-12-22 | — | — | EP | disclosed |
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | disclosed |
| WO-2004063163-A1 | 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040116694-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2004-06-17 | — | — | US | disclosed |
| WO-2003082827-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-09 | — | — | WO | disclosed |
| US-6323199-B1 | AROMATIC HETEROCYCLIC HYDROXY AMINES OR AMIDES FOR TREATMENT OF INFLAMMATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-27 | — | — | US | disclosed |
| EP-1133486-A2 | NONSTEROIDAL ANTIINFLAMMATORIES | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000032584-A2 | NONSTEROIDAL ANTIINFLAMMATORIES | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | NR3C2 2/4885NR3C1 1/4885 |
| US-20100016331-A1 | NOVEL COMPOUNDS | TSLP, LTB4R2, LTB4R | NR3C2 408/4885NR3C1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.